ChaeBio Group secures a strategic investment of 10 billion won from LG CNS to develop an AI-based digital healthcare service platform.

Target Information

ChaeBio Group, a comprehensive bio-healthcare organization, encompasses a variety of sectors including hospitals, pharmaceuticals, biotech research, and medical services. The firm operates several subsidiaries, notably ChaeBioTech, ChaeAI Healthcare, CMG Pharmaceutical, Chae Vaccine Institute, Chae Healthcare, and Chae Meditech. Furthermore, ChaeBio Group is not limited to the domestic market but also manages healthcare operations in various countries, including the United States, Singapore, Australia, and Japan.

Industry Overview in Korea

The digital healthcare industry in South Korea is witnessing significant transformation, driven by advancements in artificial intelligence (AI) and big data. Increased investment in these technologies is aimed at enhancing healthcare delivery and patient experience, making it a hub for innovative health solutions in Asia. The demand for integrating digital platforms into traditional healthcare settings has surged, reflecting a growing recognition of the benefits of data-driven decisions in clinical environments.

With a well-established healthcare infrastructure, South Korea is uniquely positioned to lead in the adoption of digital healthcare services. The government’s support in policies that foster the growth of this industry further emphasi